TY - JOUR
T1 - Blood eosinophils and lung function loss
T2 - from passive prediction to active prevention?
AU - Ramakrishnan, Sanjay
AU - Montgomery, Brett
AU - Pavord, Ian D.
N1 - Publisher Copyright:
Copyright © The authors 2024.
PY - 2024/5/1
Y1 - 2024/5/1
N2 - The blood eosinophil count has more than lived up to its potential as a prognostic and predictive biomarker in the 10 years since it earned the accolade of being biomarker of the year [1]. It is now clear that in patients already diagnosed with asthma and COPD, the blood eosinophil count predicts exacerbation frequency [2, 3], response to inhaled corticosteroids (ICS) [4, 5], the acute response to systemic corticosteroids [6], and response to monoclonal antibody therapy targeting type-2 cytokines [7, 8]. Management guided by blood eosinophil count is now the standard of care in COPD and severe asthma.
AB - The blood eosinophil count has more than lived up to its potential as a prognostic and predictive biomarker in the 10 years since it earned the accolade of being biomarker of the year [1]. It is now clear that in patients already diagnosed with asthma and COPD, the blood eosinophil count predicts exacerbation frequency [2, 3], response to inhaled corticosteroids (ICS) [4, 5], the acute response to systemic corticosteroids [6], and response to monoclonal antibody therapy targeting type-2 cytokines [7, 8]. Management guided by blood eosinophil count is now the standard of care in COPD and severe asthma.
UR - http://www.scopus.com/inward/record.url?scp=85194913200&partnerID=8YFLogxK
U2 - 10.1183/13993003.00812-2024
DO - 10.1183/13993003.00812-2024
M3 - Editorial
C2 - 38816039
AN - SCOPUS:85194913200
SN - 0903-1936
VL - 63
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 5
M1 - 2400812
ER -